| Budget Amount *help |
¥17,030,000 (Direct Cost: ¥13,100,000、Indirect Cost: ¥3,930,000)
Fiscal Year 2015: ¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2014: ¥5,720,000 (Direct Cost: ¥4,400,000、Indirect Cost: ¥1,320,000)
Fiscal Year 2013: ¥6,370,000 (Direct Cost: ¥4,900,000、Indirect Cost: ¥1,470,000)
|
|---|
| Outline of Final Research Achievements |
In this project, we explored anti-tumor therapeutic potential of novel CAR (chimeric antigen receptor)-T cell approach which combines FITC (fluorescein isothiocyanate)-labeled anti-tumor antibodies and anti-FITC CAR-T cells. Our studies demonstrated that the novel approach induces potent cytotoxic activity against tumor cells expressing multiple target molecules, and those harboring heterogeneous antigen expressions. In addition, the novel approach inhibits tumor growth by targeting neo-vasculature in tumor tissues. These results thus indicate superior anti-tumor effects and potent applicability of anti-FITC CAR-T cells as a next generation of cancer immunotherapy.
|
